FLAURA is a double-blinded, randomized clinical trial of TAGRISSO® (osimertinib) in 556 patients with locally advanced or metastatic, untreated NSCLC characterized by EGFR mutations [54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.